Get started

MiNA Therapeutics Limited (United Kingdom)

Homepage: minatx.com
Alternate names: MiNA, MiNA Therapeutics Limited
ROR: 004cs5r49
OpenAlex ID: I4405266873
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
2020 · Alexandre J. Debacker, Jon Voutila, et al. · Molecular Therapy · 427
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2020 · Debashis Sarker, Ruth Plummer, et al. · Clinical Cancer Research · 189
PDF
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
2017 · Jon Voutila, Vikash Reebye, et al. · Molecular Therapy · 129
PDF
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer
2018 · Vikash Reebye, Kai-Wen Huang, et al. · Oncogene · 109
PDF
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2021 · Ayumi Hashimoto, Debashis Sarker, et al. · Clinical Cancer Research · 103
Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile
2019 · Kai-Wen Huang, Vikash Reebye, et al. · Molecular Therapy — Nucleic Acids · 85
PDF
Developing Small Activating RNA As a Therapeutic: Current Challenges and Promises
2019 · Albert Kwok, Nina Raulf, et al. · Therapeutic Delivery · 80
Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma
2022 · Amelia L. Parker, Elise Bowman, et al. · Genome Medicine · 79
PDF
Innovative developments and emerging technologies in RNA therapeutics
2022 · François Halloy, Annabelle Biscans, et al. · RNA Biology · 57
PDF
RNA Activation—A Novel Approach to Therapeutically Upregulate Gene Transcription
2021 · Choon Ping Tan, Laura Sinigaglia, et al. · Molecules · 57
PDF
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
2018 · Ryan L. Setten, Helen L. Lightfoot, et al. · Current Pharmaceutical Biotechnology · 48
PDF
Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC
2019 · Sorah Yoon, Kai-Wen Huang, et al. · Molecular Therapy — Nucleic Acids · 40
PDF
Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice
2019 · Jiehua Zhou, Haitang Li, et al. · Molecular Therapy · 38
PDF
Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment
2022 · Yunfang Xiong, Ran Ke, et al. · Advanced Science · 33
PDF
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models
2021 · Kai-Wen Huang, Choon Ping Tan, et al. · International Journal of Molecular Sciences · 21
PDF
Treatment of Liver Cancer by C/EBPA saRNA
2017 · Xiaoyang Zhao, Jon Voutila, et al. · Advances in experimental medicine and biology · 21
Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome
2022 · Pinelopi Andrikakou, Vikash Reebye, et al. · Nucleic Acid Therapeutics · 18
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
2025 · Ruth Plummer, Mikael H. Sodergren, et al. · Cell Reports Medicine · 17
Detection of R-Loop Structures by Immunofluorescence Using the S9.6 Monoclonal Antibody
2022 · Konstantina Skourti-Stathaki · Methods in molecular biology · 17
Exploring Chemically Modified Short Activating RNAs to Increase Stability against Nucleases and Enhance Gene Activation
2025 · Jean-Paul Desaulniers, Matthew L. Hammill, et al. · Journal of Medicinal Chemistry · 6
PDF
Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile
2018 · Vikash Reebye, Kai-Wen Huan, et al. · SSRN Electronic Journal · 6
First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
2017 · Debashis Sarker, Elizabeth R. Plummer, et al. · Journal of Clinical Oncology · 5
Small activating RNA AW1-51 (CEBPA-51) elicits targeted DNA demethylation to promote gene activation
2025 · Giulia Gaggi, Juan Rodrigo Patiño-Mercau, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
RNA activation of CEBPA improves leukemia treatment
2025 · Olivia Kovecses, Bahram Sharif-Askari, et al. · Molecular Therapy — Nucleic Acids · 3
PDF
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2020 · Debashis Sarker, Mikael Sodergren, et al. · Journal of Clinical Oncology · 3
Works count: 53
Citation count: 7,911
Year
Topic
Type